Objective: The objective of the present study was to investigate the trends over time in the initial treatment of prostate cancer in Japan. Methods: A total of 8291 patients with newly diagnosed prostate cancer whose treatment started in 2010 were registered in a multi-institutional observational study undertaken nationwide across Japan by the Japan Prostate Cancer Study Group. Each patient's background characteristics and initial treatment were recorded. Results: The median age at diagnosis was 71 years. The proportion of T1c disease was 40.5% and that of M1 disease was 10.4%. The prostate-specific antigen level was ,10 ng/ml in 52.0% of the patients. High-, intermediate-and low-risk patients as determined by D'Amico's classification system made up 19.3, 29.8 and 25.9% of the cases, respectively. The initial treatment was androgen depletion therapy in 40.2%, radical prostatectomy in 32.0% (17.3% of these involved laparoscopic prostatectomy), radiation in 21.0% (46.4% of these involved brachytherapy). In cases of organ-confined disease, radical prostatectomy was selected in 39.5%, androgen depletion therapy in 28.0% and radiation in 23.9%. In D'Amico's low-risk group, the proportion treated with radiation was nearly equal to that treated with radical prostatectomy (30.2 and 32.7%, respectively); 73.2% of the radiation treatments involved brachytherapy. Conclusion: Compared with previous Japanese studies, radiation use was increased by 10%. This increased proportion of radiation use was a typical trend in initial therapy for newly diagnosed prostate cancer cases in Japan. Although androgen depletion therapy use was decreased, it was selected in a high proportion of the patients irrespective of the disease stage.
INTRODUCTION
In Japan, prostate cancer was the seventh highest cause of male cancer mortality in 2012 (1) . Although the age-adjusted mortality rate, which had rapidly increased up to 2000, began to decrease slightly in 2004, the crude mortality rate has continued to rise gradually due to the ageing population 2 -4) . Therefore, the management of prostate cancer is a very important concern for Japanese urologists. The treatment of prostate cancer has unique features that are not observed in the treatment of other malignancies. This is especially true for localized or low-risk tumors, which account for a major portion of cases of this disease, in which multiple treatment options can be effectively applied (5) . Usually, for these tumors, treatment is selected in light of several factors including patient and tumor background characteristics, the patient's preference, treatment cost and the equipment available at the institutions where treatment is to be performed (6, 7) . In the USA, where prostate cancer is diagnosed in an early stage in most cases (8) , the most frequently chosen treatment is radical prostatectomy, which is followed by radiation and androgen depletion therapy (ADT) (6) . In contrast, studies conducted more than several years ago in Japan revealed that the most frequently chosen treatment was ADT, which was followed by radical prostatectomy and radiation (9, 10) .
Over the past decade, the clinical practice patterns regarding prostate cancer have changed considerably in Japan. First, every effort has been made to achieve early detection and an early diagnosis of prostate cancer (11) . The value of prostatespecific antigen (PSA) screening has been the subject of much discussion and had become widely recognized by both physicians and among the general population (11) . Second, many new treatment technologies or devices have been introduced, and their usage has increased (5, 12, 13) . Third, new evidence concerning treatment has been accumulated (14, 15) . It is very important to investigate the recent treatment pattern in Japan because it can help us to determine how rapidly new technologies have been distributed and how new evidence or guidelines affect clinical practice. The findings might provide valuable information for patients to consider when choosing a treatment option. In addition, we can compare the patterns in Japan with those in other countries, and this comparison might form the background for the development of our original guideline. These data also provide valuable information on the analysis of socioeconomic problems that confront clinical practices.
In the present study, named the 'J-CaP2010 surveillance' study, we conducted a nationwide observational study to 
PATIENTS AND METHODS
This nationwide cross-sectional and observational study was governed by the Japan Study Group of Prostate Cancer (J-CaP). Patients fulfilling the following inclusion criteria were registered by collaborating institutions from all over Japan. The patients included were those with histologically proven prostate cancer for whom the initial main treatment was performed or started between 1 January 2010 and 31 December 2010. Each collaborating institutions were requested to register all the consecutive patients fulfilling the inclusion criteria. For each patient, the background patient and tumor characteristics and the type of treatment were recorded. The data for each subject were stored in a secured server of the J-CaP study group. A total of 140 institutions collaborated in this study. These institutions included 51 private, 52 public and 37 academic hospitals. Approval of this study was obtained from the institutional review board. Informed consent was obtained in each institution. Among 9011 registered patients, duplicate patients, patients for whom background or treatment information was lacking, and patients whose prostate biopsy was not performed between 2009 and 2010 were excluded. Thus, 8219 remaining patients were analyzed.
BACKGROUND CHARACTERISTICS
The background patient characteristics subjected to analysis included age at diagnosis, comorbidity and family history. To determine comorbidity, the presence or absence of the following disorders was recorded: hypertension, heart disease (myocardial infarction, angina pectoris and arrhythmia), stroke (infarction and bleeding), diabetes, lung disease (asthma and pulmonary emphysema), kidney disease and other malignancy (16) . The background tumor characteristics included T, N, M and clinical stages as determined by the classification system of the Union for International Cancer Control (UICC) seventh edition (17) based on pretreatment clinical information, the PSA value at diagnosis and the Gleason score. Prostate cancer risks were assessed using D'Amico's classification system (18) , the Cancer of the Prostate Risk Assessment (CAPRA) score (19) and the Japan Cancer of the Prostate Risk Assessment (J-CAPRA) score (20) .
INITIAL TREATMENT
Initial treatments were classified as radical prostatectomy, radiation, ADT, PSA surveillance and others. Others included high-intensity focused ultrasound (HIFU), chemotherapy and palliative treatment.
The types of radical prostatectomy were as follows: (i) open procedure (open retropubic or transperitoneal prostatectomy), (ii) laparoscopic procedure ( pure laparoscopic or robotassisted laparoscopic prostatectomy), (iii) minimum incision endoscopic surgery (MIES) (21) and (iv) others. Radiation was classified into two subcategories: (i) external beam radiation therapy (EBRT) (including intensity-modulated radiation therapy (IMRT), heavy-ion beam, proton beam and other EBRT), and (ii) brachytherapy (low-dose rate or highdose rate brachytherapy alone or in combination with EBRT). ADT was subdivided into two subcategories: (i) combined androgen blockade (CAB) (luteinizing-hormone releasing hormone agonist (LH-RHa) or surgical castration together with long-term anti-androgen), (ii) non-CAB (surgical castration only, LH-RHa only or LH-RHa plus short-term antiandrogen (14) , anti-androgen monotherapy and others). Combination ADT started before definitive treatment was Figure 2 . Relationships between age and treatment pattern in each risk group. Numbers in the graph represent percentages within each group. Percentages 1 are omitted. The 'Advanced' group included patients not categorized under D'Amico's risk classification system due to the presence of locally advanced disease or metastatic disease. Radical prostatectomy was most frequently chosen in patients aged ,70 years old with D'Amico's low-to high-risk disease. In these patients, the proportion of radical prostatectomy was highest in the high-risk group.
Jpn J Clin Oncol 2014;44 (10) 973 The background characteristics and treatment patterns were descriptively analyzed, and correlations between treatment patterns and background characteristics were assessed. The present data were compared with the following previous nationwide Japanese studies: (i) A study performed by the Japanese Urological Association (JUA) including 4529 patients diagnosed in 2000 (referred to as 'JUA2000' in this article) (9) 
STATISTICAL CONSIDERATION
The relationships between background characteristics and treatment patterns were assessed by using the x 2 test. The Cochran -Armitage trend test was used to test the relationships between the background characteristics and the subcategorized types of each treatment. Analyses were performed with JMP w 9 software (SAS Institute Inc., Cary, NC), and values of P , 0.05 were considered statistically significant.
RESULTS

BACKGROUND CHARACTERISTICS
Backgrounds characteristics are given in Table 1 . The median age at diagnosis was 71 (interquartile range, IQR, 66 -76) years old. T1c accounted for 40.5% of the patients. Organconfined diseases (Stage I to II) were present in 74.4% of the patients, whereas advanced diseases (Stage IV) were present in 13.6% of the patients. The median PSA value at diagnosis was 9.6 ng/ml (IQR, 6.2 -21.4). With respect to D'Amico's risk category, intermediate risk, which accounted for 29.8% of the patients, was the most common. This was followed by high risk (25.9%) and low risk (19.3%). D'Amico's classification system did not apply to 25.0% the patients, because they exhibited locally advanced and/or metastatic disease.
TREATMENT
OVERVIEW
Among 8291 patients, the most frequently chosen treatment was ADT (3337 cases, 40.2%), followed by radical prostatectomy (2657 cases, 32.0%), radiation (1741 cases, 21.0%) and PSA surveillance (527 cases, 6.4%). Other treatments (29 cases, 0.3%) included HIFU, chemotherapy and palliative treatment, which accounted for 23, 3 and 3 cases, respectively.
Relationships were observed between background characteristics and treatment patterns (Fig. 1) . Radical prostatectomy was chosen in about half of the patients aged ,70 years old, but its proportion became lower in patients aged between Jpn J Clin Oncol 2014;44(10) 975 (Fig. 1a) . Patients with low-risk disease were treated with various approaches (Fig. 1b) . It was notable that PSA surveillance was chosen in 21.4% of the patients in D'Amico's low-risk category (Fig. 1b) . The treatment pattern also depended on the type of institution (Fig. 1c) . Next, we investigated the relationships between age and treatment patterns within each of D'Amico's risk categories (Fig. 2) . In patients with low-to high-risk disease under D'Amico's classification, radical prostatectomy was most frequently and nearly consistently chosen across all age groups ,70 years old. In such patients, the proportion of patients undergoing prostatectomy was higher among intermediateand high-risk patients (60.6 to 73.3%) compared with low-risk patients (41.9 to 46.0%). In patients less than 80 years of age, radiation was chosen constitutively in all of the risk groups. In low-risk patients, PSA surveillance was chosen in 15.0 -32.5% of the cases depending on the patient's age.
RADICAL PROSTATECTOMY
Most radical prostatectomy procedures were performed by the open retropubic approach (77.3%), with the next common procedure performed by pure laparoscopic prostatectomy (17.3%) ( Table 2 ). The proportion of conventional open procedures was significantly higher in patients with poorer risk factors or in higher risk categories (P , 0.0001).
Pelvic lymph nodes were dissected in 86.8% of patients treated with radical prostatectomy. Although, this maneuver was performed in a large majority of cases in which the open retropubic approach was used (92.9%), it was also performed in 70.6 and 73.8% of the cases that underwent pure laparoscopic and robotic prostatectomy, respectively. The nervesparing technique was used in 25.9, 26.1 and 45.9% of the open retropubic, pure laparoscopic and robotic prostatectomy procedures, respectively. Neoadjuvant ADT was used in 7.8% of patients treated with radical prostatectomy.
RADIATION
EBRT was selected in 53.6% of the cases, while 46.4% of the cases were treated with brachytherapy either alone or in combination with EBRT (Table 3) . However, in patients with lower risk or in younger patients, brachytherapy was predominantly used. Among 284 patients who were in D'Amico's low-risk category and ,70 years of age, 231 (81.3%) were treated with brachytherapy. Neoadjuvant ADT was used in 22.0, 41.8 and 67.3% of the D'Amico's low-, intermediateand high-risk patients, respectively (P , 0.0001).
ANDROGEN DEPLETION THERAPY
As shown in Table 4 , ADT was performed in the form of CAB in 74.2% of the cases. Although CAB was much more frequently chosen in patients with poorer risk factors or in higher risk categories (P , 0.0001), CAB was frequently used even in Stage I (63.5%) and in D'Amico's low-risk category (56.7%). 
COMPARISON WITH PREVIOUS JAPANESE STUDIES
In the present study, the most frequently selected treatment was ADT, which was followed by radical prostatectomy, radiation and PSA surveillance. This order was the same as in previous Japanese studies (9,10) (Fig. 3) ; furthermore, the proportion of radical prostatectomy (32.0%) was close to that observed in JUA2004 (31.5%) (10) . In contrast, the proportion of radiation (21.0%) was higher than that in JUA2004 (10.4%) (10) , and that of ADT (40.2%) was lower than that in JUA2004 (49.8%) (10) . Even when differences in the background characteristics were taken into account, this trend of increased use of radiation and decreased use of ADT was still confirmed especially in localized disease. The proportion of radical prostatectomy, radiation and ADT in T1 disease were 39.0, 13.7 and 38.4% in JUA2004 (10) and 36.8, 25.7 and 25.0% in the present study, respectively.
DISCUSSION
In the present study, we investigated the current status of the initial treatment of prostate cancer in Japan. This nationwide observational study demonstrated that the most frequently selected treatment was ADT, which was followed by radical prostatectomy, radiation and PSA surveillance. Although this order was exactly the same as in previous Japanese studies (9,10), the proportion of radiation (21.0%) was higher than that in JUA2004 (10.4%) (10) , and that of ADT (40.2%) was lower than that in JUA2004 (49.8%) (10). Therefore, it was considered that a trend toward 'more definitive/curative but still conservative treatments' may be emerging in Japan.
Owing to the increased usage of brachytherapy and the advent of newly developed technology including IMRT, proton-beam radiation, and heavy-ion beam radiation, the control of cancer through radiation has been improved while various kinds of adverse events such as troublesome rectal bleeding have been reduced. These improvements in radiation therapy might be the reason for the increasing use of radiation in patients who desire 'curative but still conservative treatment'. However, as shown in Fig. 1c , treatment patterns were different by institution type, for treatment selection was affected by the equipment available at the institutions where treatment was performed. The composition of institution in the present study was different from those in the previous Japanese studies. Therefore, further longitudinal studies would be needed to confirm the aforementioned trend. The treatment patterns of prostate cancer vary considerably from country to country. By analyzing the CaPSURE data from the USA, Cooperberg et al. (6) demonstrated in 2010 that 49.9% patients underwent prostatectomy, 24.5% radiation, and 14.4% ADT. Although some changes in the treatment patterns for more curative treatments occurred in Japan, there are still big differences between Japan and the USA. One simple explanation for the difference is that more Japanese patients had advanced disease for which androgen depletion is a standard treatment option. Another explanation Jpn J Clin Oncol 2014;44 (10) 979 is that the Japanese patients were older. It is speculated that racial differences exist in the susceptibility to ADT, especially CAB, in terms of both treatment effects and side effects (22 -25) , so that ADT is also considered to be an effective treatment option in localized or locally advanced disease in the Japanese population (25, 26) . In general, the treatment option is selected based on clinicopathological background factors. The CaPSURE study demonstrated a clear relationship in which radical prostatectomy was more frequently selected as the risk became lesser (27) , as in their data it was used in 56.8, 52.9 and 32.2% of D'Amico's low-, intermediate-and high-risk patients, respectively (6) . In contrast, our results exhibited a somewhat different and complicated pattern, for radical prostatectomy was even less frequently selected in D'Amico's low-risk patients (32.7%) than in intermediate-(41.5%) and high-risk (41.7%) patients. Instead, radiation (mainly brachytherapy) was more frequently selected in low-risk patients (Figs 1b and 2) . This difference might be explained by the desire of Japanese patients to undergo conservative treatments. Owing to the public insurance system that provides universal coverage in Japan, Japanese patients do not usually hesitate to receive expensive treatments. All of these factors could explain the difference between the treatment patterns in Japan and the USA; these factors may have remained unchanged during the past decade.
In addition to the changes over time in the treatment pattern in Japan, the present study also demonstrated various changes within each treatment.
Regarding radical prostatectomy, the change observed in the present study was characterized by an increase in laparoscopic procedures and a corresponding decrease in open procedures. In Japan, laparoscopic prostatectomy was approved for coverage under public insurance in 2006 (5). Thus, laparoscopic prostatectomy use increased from 6.6% in JUA2004 (10) to 17.3% in the present study. Although the use of open prostatectomy was reduced from 89.6% (10) to 77.3%, it is still selected in the majority of prostatectomies. The type of prostatectomy in Japan contrasted with those in the USA and some other countries, where robotic prostatectomy is reported to be the most frequently used procedure (28 -30) . In Japan, robotic prostatectomy was available in only a limited number of institutions before it became covered by public insurance in 2012. Although the number of robots increased drastically to 130 in 2013, it was available in only 15 institutions as of 2010, and thus robotic prostatectomy was performed in only 2.3% of prostatectomies in the present study.
Regarding radiation, one of the most drastic changes was an increase in the use of brachytherapy (from 17.2% in JUA2004 (10) to 46.4% in the present study). It was reported that LDR brachytherapy could be performed in over 114 hospitals in Japan as of 2010 (http://www.nmp.co.jp/CGI/member/ oncoseed/hospital/list.cgi). In the present study, brachytherapy was performed in 59 institutions representing about half of all institutions where brachytherapy was available. Therefore, it is possible that brachytherapy use was overestimated to some degree in the present study. However, it is no doubt that brachytherapy has become one of the mainstays in the treatment of low-risk tumors in Japan, for brachytherapy accounted for more than half of patients ,70 years old and for 73.2% of patients with low-risk disease (Table 3) .
In the present study, CAB was selected in 74.2% of patients treated with ADT compared with 58.9 and 67.4% in J-CaP2001-3 (14) and JUA2004 (10), respectively. J-CaP2001-3 reported the proportion of CAB to be 55, 60 and 70% in Stage II, Stage III and Stage IV, respectively (14) , and the JUA2004 reported almost equivalent data (10) . In accordance with these reports, CAB was more often selected in patients with higher stages, for the proportions of CAB were 64.6, 80.7 and 86.9% in Stage I-II, Stage III and Stage IV, respectively; therefore, CAB use was increased by several percent in all stages. The increase in CAB might be due to the accumulation of evidence in the past 10 years demonstrating a survival benefit associated with CAB (14, 15) .
There are several limitations in the present study. Pathological diagnosis was not based on central pathology. The number of institutions in this study was 140, which was fewer than the 239 institutions in JUA2004 (10) and the 395 in J-CaP2001-3 (31) . The composition of institutions in the present study was different from those in the other studies. Therefore, there might be some bias in the patient selection. Nonetheless, this multi-institutional study was collaborated by various types of institutions ( private, public and academic hospitals) and consisted of over 8000 patients from all over Japan. We believe that the results obtained in this study represent valuable record of the Japanese clinical practice regarding prostate cancer.
In summary, the present study revealed that although the most frequently selected treatment was ADT, radiation use (9) and (10), respectively. As the initial therapy for newly diagnosed prostate cancer in Japan, radiation therapy made up an increased proportion and androgen depletion therapy (ADT) made up a high proportion.
980
Treatment for prostate cancer in Japan was more commonly used than in the past mainly due to the increased usage of brachytherapy for low-risk patients.
Open prostatectomy was the mainstay of radical prostatectomy techniques, while the use of laparoscopy was increased. It was concluded that the increased proportion of radiation and the high proportion of ADT irrespective of the disease stage were features of the initial therapy for prostate cancer in Japan.
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